Some new investors pitched in to Recursion Pharmaceuticals Inc.'s $121 million series C financing, adding to the industry's vision of the importance of AI and machine learning. The round was led by ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage ...
Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence ...
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $7.66, marking a +0.13% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.03%. Elsewhere, the Dow ...